Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 16, 2001, Pages 12-17

  Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GROWTH FACTOR RECEPTOR; METHOTREXATE; ONCOPROTEIN; PACLITAXEL; TRASTUZUMAB; TYROSINE KINASE RECEPTOR;

APOPTOSIS; BREAST CANCER; CELL CYCLE; CELL CYCLE G2 PHASE; CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SENSITIZATION; GENE OVEREXPRESSION; GENETIC CODE; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; ONCOGENE NEU; PRIORITY JOURNAL;

EID: 0035160330     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.28545     Document Type: Conference Paper

References (41)

1. Similarity of protein encoded by the human c-Erb-B- 2 gene to epidermal growth factor
2. The neu oncogene encodes an epidermal growth factor receptor-related protein
3. The product of the human c-ErbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
4. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
5. p185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity
6. c-neu density govern receptor interactions and tyrosine kinase activation
7. An intramembrane modulator of the ErbB 2 receptor tyrosine kinase that potentiates neuregulin signaling
8. The ErbB-3 gene product is a receptor for heregulin
9. ErB-4
10. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
11. HER-2/neu gene in human cancers
12. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
13. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
14. Neuprotein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
15. Induction of a variety of tumors by c-ErbB2 and clonal nature of lymphomas even with the mutated gene (Va165-Glu659)
16. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
17. Overexpression of the c-ErbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities
18. Prognostic importance of c-ErbB-2 expression in breast cancer
19. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
20. C-ErbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
21. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy
22. Influence of circulating c-ErbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients
23. Plasma c-ErbB2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy
24. The prognostic significance of c-ErbB-2 serum protein in metastatic breast cancer
25. mdr-1 renders breast cancer cells highly resistant to paclitaxel
26. Overexpression of c-ErbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms
27. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
28. A monoclonal antibody, against the c-ErbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines
29. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast cancer and ovarian cancer cells
30. p185cerbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair
31. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
32. Overview of the biologic markers of breast cancer
33. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
34. Phase II study of receptor- enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
35. HER2 and response to adjuvant doxorubicin chemotherapy
36. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
37. The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: Mechanisms and implications
38. Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells
39. Cdc2 kinase
40. Monoclonal antibody therapy of human cancer: Taking the HER 2 protooncogene to the clinic
41. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer